Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783
50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in
an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid
experienced individuals with current recreational use.